Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy regimens

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    787 result(s) found for: Chemotherapy regimens. Displaying page 2 of 40.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-004447-23 Sponsor Protocol Number: Parity Start Date*: 2014-03-25
    Sponsor Name:Tays [...]
    1. Tays
    2. Tays
    Full Title: Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center Randomized Controlled Study Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections with Endopro...
    Medical condition: Postoperative infection prevention
    Disease: Version SOC Term Classification Code Term Level
    16.1 10041244 - Social circumstances 10050861 Limb prosthesis user PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender:
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002716-28 Sponsor Protocol Number: 673-301 Start Date*: 2014-05-03
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic ...
    Medical condition: Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) IE (Completed) FR (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000095-26 Sponsor Protocol Number: MED-GX301-02 Start Date*: 2014-07-11
    Sponsor Name:Laboratoires Leurquin Mediolanum S.A.S.
    Full Title: A randomised, parallel-group, open-label Phase II trial of the immunological effects of three regimens of GX301 vaccination in castration-resistant prostate cancer patients who have achieved respon...
    Medical condition: Castration-resistant prostate cancer (patients who have achieved response to first-line docetaxel chemotherapy).
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001006-28 Sponsor Protocol Number: 20170770 Start Date*: 2019-09-13
    Sponsor Name:Amgen Inc.
    Full Title: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of No...
    Medical condition: non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) AT (Completed) HU (Completed) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018501-10 Sponsor Protocol Number: BAY43-9006/12444 Start Date*: 2011-03-23
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Phase III Randomized, Double blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negativ...
    Medical condition: Locally advanced or metastatic HER2-negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10004244 Benign breast neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) AT (Completed) CZ (Completed) IE (Completed) ES (Completed) HU (Completed) IT (Completed) GR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001933-16 Sponsor Protocol Number: 26866138PCR2002 Start Date*: 2007-03-13
    Sponsor Name:Christos N. Papandreou
    Full Title: "A Phase II, Open-Label study of Velcade(Bortezomib)for patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy"
    Medical condition: Treatment of patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy.
    Disease:
    Population Age: Gender: Male
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000914-19 Sponsor Protocol Number: EPO-ANE-4008 Start Date*: 2006-10-23
    Sponsor Name:Janssen-Cilag International N.V., Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatme...
    Medical condition: Anemia in cancer patients receiving chemotherapy MedDRA Version 5.1 : list of preferred terma used in the process of defining thrombotic vascular events, see investigators brochure epoetin alpha.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) SK (Completed) GR (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005182-35 Sponsor Protocol Number: BO20906 Start Date*: 2008-06-20
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chem...
    Medical condition: Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IE (Prematurely Ended) LV (Prematurely Ended) ES (Completed) BE (Prematurely Ended) AT (Completed) SK (Completed) CZ (Completed) HU (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) SE (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005803-33 Sponsor Protocol Number: TH06-001 Start Date*: 2007-01-18
    Sponsor Name:THERABEL LUCIEN PHARMA
    Full Title: ÉTUDE PILOTE OBSERVATIONNELLE CHEZ DES PATIENTES SOUFFRANT D’UN CANCER DU SEIN ET RECEVANT UNE CHIMIOTHÉRAPIE ÉMÉTISANTE TRAITÉES PAR UNE DOSE UNIQUE DE ALOXI® (PALONOSÉTRON) 0,25 MG ASSOCIÉE À UNE...
    Medical condition: The prevention of acute or delayed Chemotherapy-Induced Nausea and Vomiting (CINV) by the combination of palonosetron 250 microgrammes and methylprednisolone 80 mg in patients receiving a first adm...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10056989 Nausea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002823-15 Sponsor Protocol Number: 1968 Start Date*: 2005-10-25
    Sponsor Name:Nottingham University Hospitals NHS Trust
    Full Title: A PHASE I/II TRIAL OF THE USE OF SIROLIMUS (RAPAMUNE) AND LOW DOSE ARA-C IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML)
    Medical condition: Acute myeloid leukaemia (AML) and high risk myelodysplasia (MDS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022209-16 Sponsor Protocol Number: ICON8 Start Date*: 2011-04-08
    Sponsor Name:University College London
    Full Title: ICON8 Trials Programme ICON8: An international phase 3 randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as ...
    Medical condition: ICON8: Newly diagnosed high risk early stage (FIGO stage IC/IIA, grade 3 or clear cell histology only) or advanced stage (FIGO stage IIB-IV, all grades and all histological types) epithelial ovaria...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002992-25 Sponsor Protocol Number: 20140346 Start Date*: 2019-09-13
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of...
    Medical condition: gastrointestinal or colorectal adenocarcinoma, which includes cancers of the esophagus, stomach, colon, or rectum.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053548 Gastrointestinal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) HU (Prematurely Ended) PT (Trial now transitioned) AT (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003824-12 Sponsor Protocol Number: ProRom Start Date*: 2011-10-21
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Pilot phase II trial on safety and activity of secondary prophylaxis with Romiplostim in patients with non-Hodgkin lymphoma and chemotherapy-induced throm-bocytopenia
    Medical condition: chemotherapy-induced thrombocytopenia in patients affected by non-Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005704-29 Sponsor Protocol Number: LUNG-NEPA Start Date*: 2016-06-08
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: A standard regimen of dexamethasone in comparison to two dex-sparing regimens in addition to NEPA in preventing CINV in na¿ve NSCLC patients to be treated with cisplatin based chemotherapy: a three...
    Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) in non-small cell lung cancer (NSCLC) patients receiving a cisplatin-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10008443 Chemotherapy antiemetic prophylaxsis LLT
    21.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    21.1 10042613 - Surgical and medical procedures 10008448 Chemotherapy induced emesis prophylaxis LLT
    21.1 10042613 - Surgical and medical procedures 10049091 Chemotherapy antiemetic prophylaxis LLT
    21.1 10042613 - Surgical and medical procedures 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    21.1 10042613 - Surgical and medical procedures 10008449 Chemotherapy inducted emesis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004585-15 Sponsor Protocol Number: Cat-Ovar_2011 Start Date*: 2012-11-29
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal ca...
    Medical condition: This is an international, explorative, open-label, prospective, non-randomized multicenter phase II study to assess the feasibility and clinical activity of initial intraperitoneal catumaxomab foll...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004211-30 Sponsor Protocol Number: 2005-23 Start Date*: 2005-10-17
    Sponsor Name:The Norwegian Radium Hospital
    Full Title: Penicillin G and an aminoglycoside versus meropenem as initial empiric antibiotic therapy in lymphoma and leukemia patients with febrile neutropenia
    Medical condition: Lymphoma and leukemia patients with febrile neutropenia
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005837-13 Sponsor Protocol Number: COU-AA-301 Start Date*: 2008-06-10
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Doceta...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Docetaxel-Based Chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed) GB (Completed) FR (Completed) DE (Completed) BE (Completed) HU (Completed) AT (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004693-27 Sponsor Protocol Number: A6181064 Start Date*: 2006-11-09
    Sponsor Name:Pfizer Ltd.
    Full Title: A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS
    Medical condition: Advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) AT (Prematurely Ended) SE (Prematurely Ended) FI (Completed) FR (Completed) IT (Prematurely Ended) IE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019340-40 Sponsor Protocol Number: MOZ15609-DFI12860 Start Date*: 2010-08-23
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Phase 1/2 Combined Dose Ranging and Randomised, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cel...
    Medical condition: Paediatric cancer patients (aged 1 to <18 years) with Ewing’s sarcoma/soft tissue sarcoma, lymphoma, neuroblastoma and all other malignancies (excluding leukaemia) who are planned to undergo high d...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) BE (Completed) HU (Completed) CZ (Completed) NL (Completed) DK (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000579-10 Sponsor Protocol Number: PEANUT Start Date*: 2019-03-20
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: An open label, single-arm, phase 2 study of pembrolizumab and nanoparticle albumin-bound paclitaxel in patients with metastatic urothelial carcinoma after chemotherapy failure; the PEANUT study
    Medical condition: Advanced or metastatic urothelial carcinoma of the bladder or urinary tract relapsed or refractory to chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 19:45:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA